Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page’s site revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check23 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check51 days agoChange Detected- Revision: v3.5.0 has been added, replacing Revision: v3.4.3.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check88 days agoChange DetectedThe page shows a revision update from v3.4.1 to v3.4.2, which is a minor maintenance change. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check95 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. No visible changes to study content.SummaryDifference0.0%

Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.